A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial To Assess The Efficacy Of Oral Zolmitriptan 2.5mg In The Acute Treatment Of Migraine During The Mild Intensity Phase Of An Attack In Patients Highly Disabled By Migraine (MIDAS Grades III Or IV).

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.